Brand pharmaceutical companies sometimes agree to share profits from their patented drugs with generic manufacturers to keep rival products off the market. James Walsh and Lisa Huett consider the legality of these so-called reverse payments under Australian law in light of increasing attacks from antitrust authorities overseas
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Rebecca Newman at Addleshaw Goddard, who live-reported on the seminal dispute, unpicks the trials and tribulations of the case and considers its impact